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Abstract
Background: Persistent symptoms, mainly joint and muscular pain and depression, have been reported several months
after Chikungunya virus (CHIKV) infection. Their frequency and their impact on quality of life have not been compared with
those of an unexposed population. In the present study, we aimed to describe the frequency of prolonged clinical
manifestations of CHIKV infection and to measure the impact on quality of life and health care consumption in comparison
with that of an unexposed population, more than one year after infection.
Methodology/Principal Findings: In a retrospective cohort study, 199 subjects who had serologically confirmed CHIKV
infection (CHIK+) were compared with 199 sero-negative subjects (CHIK–) matched for age, gender and area of residence in
La Re´union Island. Following an average time of 17 months from the acute phase of infection, participants were interviewed
by telephone about current symptoms, medical consumption during the last 12 months and quality of life assessed by the
12-items Short-Form Health Survey (SF-12) scale. At the time of study, 112 (56%) CHIK+ persons reported they were fully
recovered. CHIK+ complained more frequently than CHIK– of arthralgia (relative risk = 1.9; 95% confidence interval: 1.6–2.2),
myalgia (1.9; 1.5–2.3), fatigue (2.3; 1.8–3), depression (2.5; 1.5–4.1) and hair loss (3.8; 1.9–7.6). There was no significant
difference between CHIK+ and CHIK– subjects regarding medical consumption in the past year. The mean (SD) score of the
SF-12 Physical Component Summary was 46.4 (10.8) in CHIK+ versus 49.1 (9.3) in CHIK– (p = 0.04). There was no significant
difference between the two groups for the Mental Component Summary.
Conclusions/Significance: More than one year following the acute phase of infection, CHIK+ subjects reported more
disabilities than those who were CHIK–. These persistent disabilities, however, have no significant influence on medical
consumption, and the impact on quality of life is moderate.
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Introduction
Chikungunya is a disease caused by an arboviral alphavirus
transmitted to humans by Aedes mosquitoes (Aedes aegypti, Aedes
albopictus). This disease is endemic to many countries in western,
central, eastern and southern Africa, IndianOcean andWest Pacific
Islands and South-East Asia [1]. Before 2005–2006, outbreaks of
Chikungunya had never been described on the islands of Indian
Ocean (Comoros, Mayotte, Madagascar, La Re´union, Mauritius
and Seychelles). Since then, many imported cases due to this
arbovirus were reported in areas where the disease is not endemic.
Chikungunya virus (CHIKV) is an enveloped, RNA positive-strand
Alphavirus belonging to the Togaviridae family [2]. This virus can
target human epithelial and endothelial cells, fibroblasts and
macrophages [3] and muscle progenitor cells [4], to cause a wide
range of clinical manifestations including fever, headache, rash, nausea,
vomiting, myalgia, and, especially, disabling joint pain [5,6]. CHIKV
can damage collagen and alter connective tissue metabolism in
cartilage and joints to produce severe acute arthritis. This is
characterized by necrosis and fibrosis, as indicated by high levels of
urinary proline, hydroxyproline and mucopolysaccharides observed in
patients during the acute phase of the infection [7]. In skeletal muscles,
atrophy and necrosis of scattered muscle fibres and vacuolization of
cells were shown to be potential underlying mechanisms for a myositis
syndrome [3]. Whether these phenomena can evolve towards
degenerative chronic lesions remains to be demonstrated.
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Nevertheless, several authors have reported persistent clinical
manifestations (mainly joint and muscular pain and depression)
several months after acute infection, leading some of them to
consider the possibility of chronic forms of Chikungunya infection
[5,8–13]. These persisting symptoms are not consistent among
patients and whether they are attributable to CHIKV or represent
the exacerbations of underlying conditions is still questionable.
The frequency of persisting symptoms has not been compared
with that of an unexposed population without CHIKV infection.
Moreover, the burden of such disabilities on quality of life is a
challenging, previously unrecognized problem with potentially
alarming economic consequences [14].
We conducted an investigation to describe the frequency of late
clinical manifestations of Chikungunya virus infection and to
measure the impact on quality of life and health care consumption,
compared with an uninfected population, in the context of the
epidemic occurring in La Re´union Island.
Results
Among the 434 people contacted, 27 refused to respond to the
questionnaire and 9 were excluded from the analysis because of
the impossibility of matching, leaving 199 pairs for analysis. The
participation rate was 92% (398 out of 434).
The mean age of the study population was 42 years (range: 2–
91). Table 1 shows the characteristics of the study population.
There were as many men as women, and participants were
uniformly distributed by area of residence.
Following an average time of 17 months (range: 5–28) from the
acute phase of disease, 112 of the 199 CHIK+ subjects (56%)
reported that they were fully recovered. The CHIK+ subjects aged
under 30 reported a faster recovery than the older subjects (75%
versus 40% at one year; p,0.001) (Figure 1). There was no
evidence of a difference in recovery rates between men and
women (59% versus 54%; p= 0.42).
Symptoms at the time of study are shown in Table 2. CHIK+
subjects complained significantly more often of joint pain than
CHIK– subjects (RR=1.9 [95% CI: 1.6–2.2]). The attributable
risk percent of CHIKV infection in CHIK+ subjects for arthralgia
was 46.7% (95% CI: 37.3%–54.7%). According to topographical
distribution, the pain was located in both upper and lower limbs,
but less frequently involved the spine. CHIK+ cases also reported
myalgia (RR=1.9 [1.5–2.3]), fatigue (RR=2.3 [1.8–3.0]), de-
pression (RR=2.5 [1.5–4.1]) and hair loss (RR=3.8 [1.9–7.6])
more frequently than CHIK– subjects. The attributable risk
percent of CHIKV in CHIK+ subjects was 46.4% (34.5%–56.2%)
for myalgia, 56.3% (43.5%–66.3%) for fatigue, 60% (33.8%–
75.8%) for depression and 73.7% (47.2%–86.9%) for hair loss. At
Table 1. Characteristics of the study population (199
matched pairs).
Sociodemographic
characteristics
Number of people/total number of
participants (%)
Gender
Female 202/398 (51)
Male 196/398 (49)
Age
Under 30 136/398 (34)
30 to 59 158/398 (40)
60 and over 104/398 (26)
Residential area
North 94/398 (24)
South 104/398 (26)
East 100/398 (25)
West 100/398 (25)
doi:10.1371/journal.pone.0007800.t001
Figure 1. Percentage of patients (n =199) fully recovered,
shown by age group. The long dash followed by the short dash
represents patients aged under 30; the dash represents patients aged
30 to 59 and the solid line represents those aged 60 and over. Recovery
is fast in young subjects.
doi:10.1371/journal.pone.0007800.g001
Table 2. Reported symptoms and medical consumption.
CHIK+ CHIK–
Symptoms n (%) n (%) RR* [95% CI] p-Value{
Arthralgia 105 (53) 56 (28) 1.9 [1.6–2.2] ,0.001
Upper limbs 76 (38) 29 (15) 2.6 [2.0–3.3] ,0.001
Lower limbs 83 (42) 33 (17) 2.5 [2.0–3.2] ,0.001
Spine 43 (22) 25 (13) 1.7 [1.2–2.3] 0.01
Myalgia 84 (42) 45 (23) 1.9 [1.5–2.3] ,0.001
Fatigue 71 (36) 31 (16) 2.3 [1.8–3.0] ,0.001
Depression 25 (13) 10 (5) 2.5 [1.5–4.1] 0.014
Hair loss 19 (10) 5 (3) 3.8 [1.9–7.6] 0.007
Skin disorders 20 (10) 10 (5) 2.0 [1.2–3.4] 0.087
Sleep disorders 55 (28) 39 (20) 1.4 [1.1–1.8] 0.076
Digestive disorders 12 (6) 11 (6) 1.1 [0.6–1.9] 1
Medical consumption in past twelve months
Taking analgesic 52 (26) 45 (23) 1.2 [1.0–1.4] 0.42
Medical consultations 159 (80) 169 (85) 0.9 [0.9–1.0] 0.25
Hospitalization 14 (7) 18 (9) 0.8 [0.5–1.2] 0.57
CHIK+, persons with a history of CHIKV infection confirmed by serology
(n = 199); CHIK–, persons confirmed as seronegative for CHIKV (n = 199); RR,
relative risks; CI, confidence interval.
*RR, relative risks controlling for stratification criteria.
{Exact Mac Nemar test.
doi:10.1371/journal.pone.0007800.t002
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the time of study, there was no difference between the two study
groups regarding sleep disturbances and digestive or skin
manifestations.
There was no significant difference between CHIK+ and
CHIK– subjects in the frequency of use of analgesics, medical
consultations or hospitalizations in the last 12 months (Table 2).
Quality of life was assessed in all subjects aged 15 or over
(N= 324). The average score (SD) of the physical component
summary (PCS) was significantly lower in CHIK+ subjects than
CHIK– (46.4 (10.8) versus 49.1 (9.3)) (Table 3).
Compared with the CHIK– subjects, the CHIK+ subjects’
worst score for the PCS was found in patients aged 30 to 59 and in
females (Table 3). After Bonferroni correction, however, there was
no significant difference according to age and gender. Regarding
the mental component summary (MCS), there was no difference
between CHIK+ and CHIK– subjects according to either age or
gender.
Discussion
Here we report a comparative study of longstanding disabilities
owing to CHIKV infection as they are reported within the
community. It showed that several subjective symptoms (arthral-
gia, myalgia, fatigue, depression, hair loss) reported by people
infected by CHIKV more than one year after acute infection may
be attributable largely (46.4 to 73.7%) to the past infection. The
perceived quality of life in these subjects was barely changed,
however, as demonstrated by the SF-12. In addition, CHIKV
infection was shown to have no significant impact on the use of
analgesics, medical consultations or hospitalizations.
To the best of our knowledge, no controlled survey had yet
attempted to establish the accountability of an arbovirosis, both on
the persistence of non-specific symptoms and on their impact on
quality of life in a community. Existence of a ‘‘chronic form’’ of the
disease following CHIKV infection had been suggested by
uncontrolled observational studies previously reported [5,11]
although this study design did not allow non-specific symptoms
to be attributed to the disease. The reported percentage of people
with symptoms ranged from 48% to 93% six months following
CHIKV infection [10,11] and remained up to 64% 18 months
post infection [5,15]. In addition, 15% of subjects complained of
persistent arthralgia 20 months after infection [8], while 12%
complained of residual symptoms such as pain and/or stiffness
more than three years later [16]. In these reports, the causal
relationship of such symptoms with CHIKV infection is
questionable owing to participation and selection biases, absence
of standardization in symptom elicitation, lack of clinical review
and the absence of a control group. Moreover, specificity of
reported clinical manifestations may be limited. For example, the
prevalence of self-reported musculoskeletal pain lasting for more
than one week in the past month, including rheumatic symptoms,
was 47% in an otherwise healthy adult population in the UK [17].
With such a large prevalence of rheumatic symptoms in the
community, these symptoms are likely to occur frequently in
subjects long after a Chikungunya virus infection even without a
causal relationship.
Chronic symptoms following infection with other ‘‘arthrito-
genic’’ alphaviruses such as Ross River virus and Sindbis-related
virus have been reported previously in series of case studies
[13,18–23]. Concurrently, following the reports of long-term
clinical manifestations of Ross River virus disease, two prospective
longitudinal studies were conducted, one of them based on clinical
review [24,25]. It was concluded that earlier studies may have
overestimated the prevalence and duration of these symptoms,
showing their progressive resolution within three to six months.
Moreover, conditions such as chronic rheumatic disease or
depression were identified in half the cohort. In a previous study
reporting on the persistent arthralgia associated with CHIKV
infection, 44% of patients reported a prior history of joint
symptoms which made it difficult to establish the real increase in
symptomatic functional manifestations [5]. Similarly, Sissoko et al.
identified the presence of underlying osteoarticular comorbidity as
a significant risk factor for non recovery [15]. That is why the
possibility of overlap between a rheumatic pre-existing underlying
condition and an authentic Chikungunya-related arthralgia led the
most skeptical authors to think that prolonged signs of ‘‘arthrito-
genic’’ alphaviruses could represent the neglected mode of entry of
a rheumatic disease, such as rheumatoid arthritis or psoriasic
rheumatism [5,19,22,24].
The basis for the musculoskeletal symptoms of Chikungunya
disease is still poorly understood [26]. To the best of our
knowledge, the presence of CHIKV in human synovial tissue
has never been reported, although there is some evidence that
CHIKV can damage the cartilage and has a tropism for the
fibroblasts of joint capsule and skeletal muscle [7,27]. One of the
recurrent symptoms of the disease is myalgia. In patients with
myositis syndrome, three to four months after the acute phase of
the infection, viral antigens were found selectively inside skeletal
muscle satellite cells, a type of cell responsible for postnatal muscle
growth and repair [4]. It has been hypothesised that infection of
these cells might have pathological consequences for long-term
myalgia in infected patients. A recent animal model also
Table 3. Quality of life assessment by the SF-12 of subjects
with a history of Chikungunya virus infection compared with
uninfected subjects.
CHIK+ CHIK–
SF-12 component
summaries
mean score
(SD)
mean score
(SD) p-Value*
Physical Component
Summary
46.4 (10.8) 49.1 (9.3) 0.04
Age
Under 30 53.4 (5.1) 52.8 (6.0) 0.66{
30 to 59 46.0 (10.4) 50.2 (8.2) 0.02{
60 and over 42.5 (11.9) 45 (11.0) 0.35{
Gender
Female 45 (11.2) 48.9 (9.6) 0.02{
Male 47.9 (10.0) 49.2 (9.0) 0.71{
Mental Component
Summary
45.5 (11.1) 45.6 (10.1) 0.83
Age
Under 30 46.4 (9.7) 46.1 (9.5) 0.97{
30 to 59 43.9 (11.7) 44.7 (9.5) 0.58{
60 and over 47.3 (10.9) 46.4 (11.4) 0.84{
Gender
Female 43.8 (11.2) 43.9 (10.8) 0.81{
Male 47.5 (10.8) 47.2 (9.1) 0.91{
CHIK+, persons with a history of CHIKV infection confirmed by serology
(n = 162); CHIK–, persons confirmed as seronegative for CHIKV (n = 162).
*Wilcoxon’s rank test for paired samples.
{After Bonferroni correction, the statistical significance was then set at p = 0.01
with a bilateral formulation.
doi:10.1371/journal.pone.0007800.t003
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demonstrated the presence of CHIKV antigens within young mice
muscles several weeks following infection [28]. The pathogenic
significance of these observations still needs to be clarified. As
suggested by some authors, the muscle and joint connective tissues
targeted by the virus contain high amounts of nociceptive nerve-
endings that may account for the muscle and joint pain [27].
A post-infective fatigue syndrome similar to the symptoms
reported here by CHIK+ patients (i.e. disabling fatigue, muscu-
loskeletal pain, neurocognitive difficulties and mood disturbance)
has been shown to persist for six months or more in 12% of
persons following a variety of acute infections, including Ross
River virus [29]. It seems to routinely occur at a similar incidence
after each infection and to be predicted mostly by the severity of
the acute phase of illness. Thus, the high frequency of such late
symptoms following CHIKV infection could simply reflect the fact
that the symptoms of the acute phase of CHIKV infection are
usually more severe and incapacitating than other common viral
infections [30]. The neurobiological mechanisms that could
explain this post-infective fatigue syndrome remain to be
determined [29].
Little attention was paid to scalp lesions in CHIKV infection.
However, in the field of alphaviral infections, hair loss is consistent
with alopecia encountered in a mice model of Chikungunya
infection [28] and in one of O’ Nyong - Nyong fever [31]. The
basis for this symptom following Chikungunya infection is not
understood. It could simply reflect a non specific symptom
triggered by the acute febrile illness, as observed after many
systemic diseases [32].
Quality of life was already assessed with the SF-12 in other
rheumatic conditions, such as rheumatoid arthritis, osteoarthritis
and fibromyalgia [33–35]. In these diseases, patients usually had
an MCS above 40, as observed in CHIKV-infected individuals.
The PCS of rheumatological patients, however, frequently lay
around 30, which is a much lower (i.e. poorer) score than that
observed among Chikungunya cases. The relatively well preserved
quality of life of CHIK+ patients is illustrated by the fact that more
than a year after the onset of infection, Chikungunya-associated
symptoms were not associated with any increase in health care
consumption. This is a reassuring finding, although we cannot
exclude the possibility that CHIK+ patients engaged in higher use
of alternative medicines, such as herbal medicines [36]. It is
also likely that this finding reflects an adaptive coping strategy
to manage chronic symptoms without additional medical
consumption.
There is no clear explanation why patients under the age of 30
reported faster recovery compared to those older than 30. Older
age and severe initial joint pain have been recognized as risk
factors for non-recovery [15], and older patients can experience
more severe acute infections than younger patients. Indeed,
inpatients with acute infections during the La Re´union outbreak
were older than outpatients (64 versus 48 years respectively,
p = 0.001) [6]. Finally, underlying medical conditions such as
osteoarthritis, whose prevalence increases with age, could also
result in delayed recovery [15].
Our report has some strengths and limitations. The investigator
was not blinded to the serological status of the subjects;
participants were questioned about symptoms long after the acute
phase of the disease. Also patients were not examined so
alternative diagnoses could not be excluded. However, in contrast
with previous studies, a standardized health status questionnaire
was used and administered by only one investigator, a validated
generic quality of health assessment tool was used (the SF-12), a
control group was included for comparison and participants were
randomly selected through a population-based cohort [37]. There
was no substantial participation bias favouring patients with more
severe illness, whereas previous studies had included patients who
presented severe forms of CHIKV infection, often requiring
hospitalization, and who were thus not representative of the
general population. The diagnostic accuracy of CHIKV infection
was efficient, as it has been reported that during La Re´union’s
epidemic the incidence of asymptomatic cases (i.e. all subjects who
were not aware of their infection during the epidemic period but
were tested serologically positive to CHIKV) and the rate of false
positives (i.e. subjects who declared that they were infected during
the epidemic period but had negative serology) were lower than
5% [10,37].
Whilst there is appreciable temporary disability associated with
acute CHIKV infection, and even though more frequent
manifestations are reported by infected persons more than a year
after the acute phase of the condition, the resulting impact on
quality of life and medical consumption seems moderate. Despite
alarming signs observed throughout the outbreak in La Re´union,
such as reports of severe atypical forms[38,39], mother-to-child
intra partum transmission [40] and increased mortality [41], these
results reintroduce Chikungunya in the field of ‘‘benign’’ illnesses.
Further research, most appropriately population-based studies
using clinical reviews, is required to better understand the natural
history, pathogenesis and long-term impact of persisting manifes-
tations following CHIKV infection.
Materials and Methods
Study design and population
We conducted a retrospective cohort study to compare subjects
who had been infected by CHIKV during the 2005 and 2006
outbreaks in La Re´union Island with those who had not been
infected. The study sample was derived from the SEROCHIK
survey, a cross-sectional, population-based seroprevalence study
aimed at assessing the prevalence of CHIKV infection in the
community soon after the 2006 outbreak [37]. This survey
involved a representative sample of 2442 people for whom the
history of Chikungunya infection was recorded and a serological
test performed using an ELISA assay [42]. In this survey, the
sensitivity of CHIKV specific-IgG serology was 97.9% (95% CI:
88.7–99.9%) and the specificity 100% (96.0–100%) [37].
From this population, we selected pairs of subjects with one
subject with serologically confirmed CHIKV infection (CHIK+)
and one matched subject with negative serology (CHIK–). Pairs of
subjects were obtained by balanced random sampling without
replacement from 24 strata defined by a unique combination of
age (,30 years old, 30 to 59 years and $60 years), gender and
area of residence (north, south, east and west of the island area).
Setting
La Re´union is a French overseas department of 787,836
inhabitants located on a volcanic island of 2511 km2 belonging to
the Mascarene Islands in the south-western Indian Ocean.
Between 2005 and 2006, a Chikungunya outbreak occurred in
La Re´union, in which 38.2% of inhabitants became infected [37].
Data collection
Participants were interviewed by telephone between March and
June 2007. The questionnaire was administered by one investiga-
tor (MKS), using closed questions addressing current symptoms,
medical consumption during the last 12 months (consultation,
hospitalization and use of analgesics) and quality of life assessed by
the SF-12 scale [43].
Impact of Chikungunya Virus
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The patients were questioned about the presence or absence of
symptoms on the day of the telephone interview. Illness history
was recorded during the interview using questions formulated in
lay terms. They were asked if they were currently experiencing the
following: joint pain (for arthralgia), muscle aches (for myalgia),
fatigue, depression, hair loss, skin disorders, sleep disorders or
digestive disorders such as nausea, vomiting or diarrhea. When
patients reported presence of arthralgia, they were asked to
localize the involved joints.
The SF-12 explores the physical and mental aspects of quality of
life [17]. The physical component summary (PCS) assesses
physical functioning difficulties caused by physical problems,
bodily pain and general health. The mental component summary
(MCS) assesses vitality, social functioning and role functioning
difficulties caused by emotional problems and mental health. The
PCS and MCS are standardized to reflect a general population
mean of 50 and a standard deviation of 10. Higher scores indicate
better functioning [44].
For children under eight, the questionnaire was completed by
parents. The SF-12 scale addresses only people of 16 years and
over.
Sample size and statistical analysis
We considered that an absolute difference of 15% in the
frequency of musculoskeletal (e.g. arthralgia or myalgia) symptoms
between CHIK+ and CHIK– subjects would be of interest. It has
been reported that about 45% of the adult population suffer
musculoskeletal pain [18] and the sample size calculation for a 5%
type 1 error and a 20% type 2 error yielded 186 subjects in each
group. For practical reasons, we finally decided to include 400
subjects (200 CHIK+ and 200 CHIK–).
Assessment of explanatory variables was conducted by univar-
iate analysis. For paired samples, qualitative variables were
analysed using exact Mac Nemar’s test and continuous variables
(SF-12 components) were analysed using Wilcoxon’s rank test.
Adjusted relative risks (RR) and their 95% confidence interval
(95% CI) were calculated for each persisting symptom controlling
for stratification criteria (age, gender, and area of residence) using
Mantel-Haenszel methods [45]. Attributable risk percents (ARP%)
and their 95% CI were calculated for each significant persisting
symptom to assess the accountability of CHIKV infection, as
follows: ARP%= (RR21)/RR6100. We used the Kaplan-Meier
method to estimate the time to full recovery in CHIK+ patients
and the factors influencing the recovery time. Statistical signifi-
cance was set at p= 0.05 with a bilateral formulation.
For the evaluation of quality of life, specific analyses were
conducted separately in groups based on sex and age. We then
performed five tests adjusted by Bonferroni correction and the
statistical significance was set at p= 0.01 with a bilateral
formulation.
EpiData 3.1TM software (EpiData Association, Copenhagen,
2003) was used for data entry and Stata 10.0TM software
(StataCorp. 2008, Texas, USA) for analysis.
Ethical considerations
During the SEROCHIK survey, which had received ethical
approval, the participating subjects had been informed that they
might be called back for ancillary research. During the telephone
interview, the objectives of the study were presented and oral
consent to participate was obtained. For people under the age of
18, the inform consent form was completed by parents.
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